{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04855656",
            "orgStudyIdInfo": {
                "id": "RP-6306-01"
            },
            "organization": {
                "fullName": "Repare Therapeutics",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of RP-6306 Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors",
            "officialTitle": "Phase 1/1b Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-6306 Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors",
            "acronym": "MYTHIC",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "study-of-rp-alone-or-in-combination-with-rp-or-debio-in-patients-with-advanced-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-04-30",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-06-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-04-09",
            "studyFirstSubmitQcDate": "2021-04-19",
            "studyFirstPostDateStruct": {
                "date": "2021-04-22",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-10",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-15",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Repare Therapeutics",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "Debiopharm International SA",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The primary purpose of this study is to assess the safety and tolerability of RP-6306 alone and in combination with RP-3500 or in combination with Debio 0123 in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.",
            "detailedDescription": "Phase 1/1b, multi-center, open-label, dose-escalation study to:\n\n* Evaluate the safety profile and MTD of RP-6306 alone and in combination with RP-3500 or in combination with Debio 0123 when administered orally to establish the recommended Phase 2 dose and schedule\n* Characterize the PK and pharmacodynamics of RP-6306 alone and in combination with RP-3500 or in combination with Debio 0123\n* Assess preliminary anti-tumor activity associated with RP-6306 alone and in combination with RP-3500 or in combination with Debio 0123"
        },
        "conditionsModule": {
            "conditions": [
                "Advanced Solid Tumor"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 364,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Phase 1: RP-6306 Single-Agent, Dose Escalation and Food-effect Study",
                    "type": "EXPERIMENTAL",
                    "description": "Patients receive RP-6306 orally until disease progression, unacceptable toxicity, or investigator/patient decision. Dose escalation will proceed until a maximum tolerated dose is identified.",
                    "interventionNames": [
                        "Drug: RP-6306"
                    ]
                },
                {
                    "label": "Phase 1: RP-6306 in combination with RP-3500, Dose Escalation Study",
                    "type": "EXPERIMENTAL",
                    "description": "Patients receive RP-6306 with RP-3500 orally until disease progression, unacceptable toxicity, or investigator/patient decision. Dose escalation will proceed until a maximum tolerated dose is identified.",
                    "interventionNames": [
                        "Drug: RP-6306",
                        "Drug: RP-3500"
                    ]
                },
                {
                    "label": "Phase 1: RP-6306 in combination with Debio 0123, Dose Escalation Study",
                    "type": "EXPERIMENTAL",
                    "description": "Patients receive RP-6306 with Debio 0123 orally until disease progression, unacceptable toxicity, or investigator/patient decision. Dose escalation will proceed until a maximum tolerated dose is identified.",
                    "interventionNames": [
                        "Drug: RP-6306",
                        "Drug: Debio0123"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "RP-6306",
                    "description": "Oral PKMYT1 Inhibitor",
                    "armGroupLabels": [
                        "Phase 1: RP-6306 Single-Agent, Dose Escalation and Food-effect Study",
                        "Phase 1: RP-6306 in combination with Debio 0123, Dose Escalation Study",
                        "Phase 1: RP-6306 in combination with RP-3500, Dose Escalation Study"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "RP-3500",
                    "description": "Oral ATR Inhibitor",
                    "armGroupLabels": [
                        "Phase 1: RP-6306 in combination with RP-3500, Dose Escalation Study"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Debio0123",
                    "description": "Oral WEE1 Inhibitor",
                    "armGroupLabels": [
                        "Phase 1: RP-6306 in combination with Debio 0123, Dose Escalation Study"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Safety and Tolerability of RP-6306 either in monotherapy or in combination with RP-3500 or with Debio 0123 in patients with eligible advanced solid tumors",
                    "description": "Assessed by treatment-emergent adverse events (TEAEs), physical examinations (PEs), safety laboratory assessments, electrocardiograms (ECGs), and vital sign measurements",
                    "timeFrame": "Up to 90 days after last administration of study intervention"
                },
                {
                    "measure": "To define the MTD of RP-6306 monotherapy, and determine a recommended Phase 2 dose (RP2D) and preferred schedule",
                    "description": "Assessed by the incidence of Dose-limiting toxicities (DLTs) and the incidence and severity of cumulative safety data",
                    "timeFrame": "Up to 90 days after last administration of study intervention"
                },
                {
                    "measure": "To define the MTD of RP-6306 in combination with RP-3500 or in combination with Debio 0123, and determine a recommended Phase 2 dose (RP2D) and preferred schedule",
                    "description": "Assessed by the incidence of dose-limiting toxicities (DLTs) and the incidence and severity of cumulative safety data",
                    "timeFrame": "Up to 90 days after last administration of study intervention"
                },
                {
                    "measure": "The relative bioavailability of RP-6306 capsule formulation as compared to RP-6306 tablet formulation in the fasted state",
                    "description": "Assessed by the plasma concentrations of RP-6306 with calculation of pharmacokinetic (PK) parameters including maximum observed plasma concentration (Cmax), time to maximum observed plasma concentration (Tmax), area under the plasma concentration-time curve (AUC) , for both formulations in the fasted state.",
                    "timeFrame": "Time 0 (time of dosing) to 72 hours post-dose for each treatment condition"
                },
                {
                    "measure": "The effect of food on the PK of tablet formulation of RP-6306 when administered in fed conditions compared to administration under fasted conditions",
                    "description": "Assessed by the plasma concentrations of RP-6306 with calculation of the ratio of PK parameters (e.g., Cmax and AUC) between the tablet formulation under fasted and fed state.",
                    "timeFrame": "Time 0 (time of dosing) to 72 hours post-dose for each treatment condition"
                },
                {
                    "measure": "To assess the safety and tolerability of RP-6306 tablets in combination with RP-3500, confirm the MTD of RP-6306 tablets in combination with RP-3500, and determine a RP2D and preferred schedule",
                    "description": "Assessed by DLTs, TEAEs, safety laboratory assessments, the incidence of DLTs and the incidence and severity of cumulative safety data",
                    "timeFrame": "Up to 90 days after last administration of study intervention"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "The plasma concentrations of RP-6306 monotherapy (capsule formulation) in the fasted and fed states",
                    "description": "Assessed by the plasma concentrations of RP-6306 with calculation of maximum observed plasma concentration (Cmax), time to maximum observed plasma concentration (Tmax), minimum observed plasma concentration (Cmin), area under the plasma concentration-time curve (AUC), elimination half-life (t1/2), and other parameters as appropriate",
                    "timeFrame": "Up to 90 days after last administration of study intervention"
                },
                {
                    "measure": "To assess the relationship between pharmacodynamic biomarkers and PK of RP-6306 at different dose levels and/or schedules",
                    "description": "Assessed by evaluation of biomarkers in pre- and on-treatment biopsies, and circulating tumor DNA (ctDNA) dynamics during treatment",
                    "timeFrame": "Up to 90 days after last administration of study intervention"
                },
                {
                    "measure": "The plasma concentrations of RP-6306 and RP-3500 when dosed in combination",
                    "description": "Assessed by the plasma concentrations of RP-6306 and RP-3500 with calculation of maximum observed plasma concentration (Cmax), time to maximum observed plasma concentration (Tmax), minimum observed plasma concentration (Cmin), area under the plasma concentration-time curve (AUC), elimination half-life (t1/2), and other parameters as appropriate for each analyte",
                    "timeFrame": "Up to 90 days after last administration of study intervention"
                },
                {
                    "measure": "To assess preliminary anti-tumor activity achieved with RP-6306 monotherapy, RP-6306 in combination with RP-3500 or RP-6306 in combination with Debio 0123",
                    "description": "Measured by best percent change in tumor size from baseline, objective response rate (ORR), overall response rate, tumor marker response, duration of response (DOR), clinical benefit rate (CBR), progression-free survival (PFS).",
                    "timeFrame": "Through Study Completion, an average of 1 year"
                },
                {
                    "measure": "To assess the safety and anti-tumor effects of RP-6306 capsule + RP-3500",
                    "description": "As measure by TEAEs, safety laboratory assessments, Best percent change in tumor size from baseline, ORR, overall response rate, DOR, CBR, tumor marker response, PFS",
                    "timeFrame": "Through Study Completion, an average of 1 year"
                },
                {
                    "measure": "To further characterize the PK of RP-6306 tablets and assess preliminary anti-tumor",
                    "description": "Measured by Plasma concentrations of RP-6306 with calculation of Cmax, Tmax, AUC, elimination t1/2, and other PK parameters as appropriate, Best percent change in tumor size from baseline, ORR, overall response rate, DOR, CBR, tumor marker response, PFS",
                    "timeFrame": "Through Study Completion, an average of 1 year"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female and \u226512 years-of-age at the time of informed consent.\n* Lansky performance status \u226550% for patients \u226416 years of age, or ECOG score of 0, 1, (or 2 for module 1) for patients \\>16 years of age.\n* Locally advanced or metastatic resistant or refractory solid tumors.\n* Patients \\<18 years of age must weigh at least 40 kg.\n* Submission of available tumor tissue at screening or willingness to have a biopsy performed if safe and feasible\n* Next generation sequencing (NGS) report obtained in a CLIA-certified or equivalent laboratory demonstrating eligible tumor biomarker.\n* CCNE1 amplification (non-equivocal) as determined by either a tumor or plasma NGS test, or FISH\n* FBXW7 deleterious mutations identified by either a tumor or plasma NGS test\n* PPP2R1A deleterious mutations identified by either a tumor or plasma NGS test\n* Measurable disease as per RECIST v1.1. For certain modules, patients with prostate cancer or ovarian cancer that have non-measurable disease but have elevated tumor markers (PSA or CA-125, respectively) can also be eligible\n* Ability to swallow and retain oral medications.\n* Acceptable hematologic and organ function at screening.\n* Negative pregnancy test (serum) for women of childbearing potential (WOCBP) at Screening.\n* Resolution of all toxicities of prior therapy or surgical procedures.\n* Any prior radiation must have been completed at least 7 days prior to the start of study drugs, and patients must have recovered from any acute adverse effects prior to the start of study treatment.\n\nExclusion Criteria:\n\n* Chemotherapy or small molecule antineoplastic agent given within 21 days or \\<5 half-lives, whichever is shorter, prior to first dose of study drug.\n* History or current condition, therapy, or laboratory abnormality that might confound the study results or interfere with the patient's participation for the full duration of the study treatment.\n* Patients who are pregnant or breastfeeding.\n* Life-threatening illness, medical condition, active uncontrolled infection, or organ system dysfunction or other reasons which, in the investigator's opinion, could compromise the participating patient's safety.\n* Major surgery within 4 weeks prior to first dose of RP-6306.\n* Uncontrolled, symptomatic brain metastases.\n* Uncontrolled hypertension.\n* Certain prior anti-cancer therapy\n* Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol and/or follow-up procedures outlined in the protocol.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "12 Years",
            "stdAges": [
                "CHILD",
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Nathan Hawkey, MD, MBA",
                    "role": "CONTACT",
                    "phone": "+1 (857) 340-5402",
                    "email": "clininfo@reparerx.com"
                }
            ],
            "locations": [
                {
                    "facility": "Participating Site # 1012",
                    "status": "RECRUITING",
                    "city": "New Haven",
                    "state": "Connecticut",
                    "zip": "06520",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.30815,
                        "lon": -72.92816
                    }
                },
                {
                    "facility": "Participating site # 1002",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02215",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Participating site #1011",
                    "status": "RECRUITING",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63130",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                },
                {
                    "facility": "Participating Site # 1008",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10032",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Participating Site # 1004",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Participating Site # 1010",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19104",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                },
                {
                    "facility": "Participating Site # 1007",
                    "status": "RECRUITING",
                    "city": "Providence",
                    "state": "Rhode Island",
                    "zip": "02903",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.82399,
                        "lon": -71.41283
                    }
                },
                {
                    "facility": "Participating Site # 1030",
                    "status": "RECRUITING",
                    "city": "Providence",
                    "state": "Rhode Island",
                    "zip": "02903",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.82399,
                        "lon": -71.41283
                    }
                },
                {
                    "facility": "Participating Site # 1001",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Participating Site #1013",
                    "status": "RECRUITING",
                    "city": "Salt Lake City",
                    "state": "Utah",
                    "zip": "84112",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.76078,
                        "lon": -111.89105
                    }
                },
                {
                    "facility": "Participating Site, # 1027",
                    "status": "RECRUITING",
                    "city": "Charlottesville",
                    "state": "Virginia",
                    "zip": "22903",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.02931,
                        "lon": -78.47668
                    }
                },
                {
                    "facility": "Participating site # 2002",
                    "status": "RECRUITING",
                    "city": "Toronto",
                    "state": "Ontario",
                    "zip": "M5G 1X8",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 43.70011,
                        "lon": -79.4163
                    }
                },
                {
                    "facility": "Participating site #2001",
                    "status": "RECRUITING",
                    "city": "Toronto",
                    "state": "Ontario",
                    "zip": "M5G 2C1",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 43.70011,
                        "lon": -79.4163
                    }
                },
                {
                    "facility": "Participating Site #4001",
                    "status": "RECRUITING",
                    "city": "Copenhagen",
                    "country": "Denmark",
                    "geoPoint": {
                        "lat": 55.67594,
                        "lon": 12.56553
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ]
        }
    },
    "hasResults": false
}